Study Finds No Significant Benefit of Mucoactive Agents in Preventing Lung Flare-Ups in Bronchiectasis Patients
A recent study finds that hypertonic saline and carbocisteine do not significantly reduce lung flare-ups in bronchiectasis patients, guiding future treatment strategies.
Research led by Queen's University Belfast has investigated the effectiveness of mucoactive therapies—specifically hypertonic saline and carbocisteine—in managing bronchiectasis, a chronic lung condition characterized by persistent cough, sputum production, chest pain, and recurrent exacerbations that can impair quality of life. The multicenter trial, published in the New England Journal of Medicine, involved 288 adults across 20 UK hospitals and aimed to determine whether these treatments could reduce pulmonary flare-ups over a year.
Participants were randomized to receive either hypertonic saline, carbocisteine, both, or standard care without additional mucoactive agents. Hypertonic saline was administered via nebulizer, while carbocisteine was dosed at 750 mg thrice daily for eight weeks, then twice daily. Notably, smokers and recent mucoactive users were excluded to eliminate confounding factors.
The primary outcome measured was the number of pulmonary exacerbations, assessed using standardized criteria. Results revealed no statistically significant difference in exacerbation rates between the groups. The adjusted difference for hypertonic saline versus no saline was -0.25 (95% CI -0.57 to 0.07, P=0.12), and for carbocisteine versus no carbocisteine, it was -0.04 (95% CI -0.36 to 0.28, P=0.81). Secondary measures, such as quality-of-life scores and lung function, showed no notable differences.
The study concludes that adding these mucoactive treatments to standard care does not effectively reduce exacerbation frequency in bronchiectasis. These findings emphasize the need for clinicians and patients to consider treatment burdens, costs, and side effects when choosing management strategies, potentially guiding a shift away from routine use of these agents for exacerbation prevention.
This research supports the ongoing reassessment of mucoactive therapies and underscores the importance of evidence-based treatment choices in respiratory care.
For more detailed information, see the original study: Judy M. Bradley et al, "Hypertonic Saline or Carbocisteine in Bronchiectasis," New England Journal of Medicine (2025). Source: https://medicalxpress.com/news/2025-09-mucoactive-bronchiectasis-treatments-benefit-lung.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Advancements in 3D-Printed Lung Models for Better Disease Study and Treatment
Researchers are developing 3D-printed lung models that could revolutionize disease study and personalized treatment, paving the way for improved therapies and potential lung regeneration.
Gene Variant Providing Protection Against Heart Diseases Offers Hope for Safer Therapies
Genetic variations in the IL6 gene suggest that reducing IL-6 activity can lower cardiovascular risk without increasing infection susceptibility, supporting safer therapeutic strategies.
Federal Changes to Medicaid Work Requirements Limit State Flexibility
New federal Medicaid work requirements introduced in 2025 are restricting states' ability to customize their programs, emphasizing a more uniform national approach while influencing Medicaid coverage across the country.
President Trump Announces Plan to Sign Executive Order Aiming to Reduce US Drug Prices
President Trump announced plans to sign an executive order implementing a 'Most Favored Nation' policy, aiming to significantly reduce prescription drug prices in the US by linking them to the lowest prices paid internationally.